Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer

Urologic Clinics of North America

Volumn 27, Issue 1, 2000, Pages 137-146

  Dalbagni, Guido ^b   Herr, Harry W ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; MITOMYCIN C;

BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; HUMAN; LONG TERM CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0033949998     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70241-X     Document Type: Article

References (47)

1. C. Anderstrom S. Johansson S. Nilsson The significance of lamina propria invasion on the prognosis of patients with bladder tumors J Urol 124 1980 23 26
2. M. Ayed L. Ben Hassine R. Ben Slama Resultats du BCG dans le traitement des tumeurs de vessie pTa et pT1: Evaluation d'un protocole long utilisant 75 mg de BCG de souche Pasteur Prog Urol 8 1998 206 210
3. R.A. Badalament H.W. Herr A.Y. Wong A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer J Clin Oncol 5 1987 441 449
4. L. Boccon-Gibod C. Leleu J.M. Herve Bladder tumors invading the lamina propria (stage A/T1): Influence of endovesical bacillus Calmette-Guerin therapy on recurrence and progression Eur Urol 16 1989 401 404
5. P.R. Bretton H.W. Herr M. Kimmel The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin J Urol 143 1990 710 712
6. T.T. Bui P.F. Schelhammer Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response Urology 49 1997 687 690
7. W.J. Catalona M.A. Hudson D.P. Gillen Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer J Urol 137 1987 220 224
8. M.S. Cookson M.F. Sarosdy Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin J Urol 148 1992 797 801
9. D.E. Coplen M.D. Marcus J.A. Myers Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: Analysis of possible predictors of response free tumor J Urol 144 1990 652 657
10. G.R. Eure M.R. Cundiff P.F. Schellhammer Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer J Urol 147 1992 376 379
11. E.O. Haaff S.M. Dresner T.L. Ratliff Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder J Urol 136 1986 820 824
12. N.M. Heney S. Ahmed M.J. Flanagan for the National Bladder Cancer Collaborative Group A (NBCCGA) Superficial bladder cancer: Progression and recurrence J Urol 130 1983 1083 1086
13. H.W. Herr V.P. Laudone R.A. Badalament Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer J Clin Oncol 6 1988 1450 1454
14. H.W. Herr R.A. Badalament D.A. Amato Superficial bladder cancer treated with bacillus Calmette-Guerin: A multivariate analysis of factors affecting tumor progression J Urol 141 1989 22 29
15. H.W. Herr G. Jakse J. Sheinfeld The T1 bladder tumor Semin Urol 8 1990 254 261
16. H.W. Herr Tumour progression and survival in patients with T1G3 bladder tumours: 15 Year outcome Br J Urol 80 1997 762 765
17. M.A. Hudson T.L. Ratliff D.P. Gillen Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: A prospective randomized trial J Urol 138 1987 295 298
18. R. Hurle A. Losa A. Ranieri Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy J Urol 156 1996 1602 1605
19. K. Ick M. Schultz P. Stout Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment Urology 49 1997 541 547
20. G. Jakse W. Loidl G. Seeber Stage T1, grade 3 transitional cell carcinoma of the bladder: An unfavorable tumor? J Urol 137 1987 39 43
21. J.F. Jimenez-Cruz C.D. Vera-Donoso O. Leiva Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage T1): Multicenter trial comparing bacille Calmette-Guerin and interferon-alpha Urology 50 1997 529 535
22. S. Krege G. Giani R. Meyer A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin J Urol 156 1996 962 966
23. L. Lacombe G. Dalbagni Z.F. Zhang Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: Correlation to clinical outcome J Clin Oncol 14 1996 2646 2652
24. D.L. Lamm M.F. Sarosdy E.D. Grossman Maintenance vs nonmaintenance BCG immunotherapy of superficial bladder cancer: A Southwest Oncology Group study [abstract] J Urol 143 1990 341
25. D.L. Lamm B.A. Blumenstein D.E. Crawford A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional cell carcinoma of the bladder N Engl J Med 325 1991 1205 1209
26. S.H. Landis T. Murray S. Bolden Cancer statistics, 1999 CA Cancer J Clin 49 1999 8 31
27. T. Lebret V. Becette M. Barbagelatta Correlation between p53 overexpression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer J Urol 159 1998 788 791
28. C. Lundholm B.J. Norlen P. Ekman A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 156 1996 372 376
29. P.-U. Malmstrom H. Wijkstrom C. Lundholm members of the Swedish-Norwegian Bladder Cancer Study Group 5-Year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 161 1999 1124 1127
30. J.A. Martinez-Pineiro E. Solsona N. Flores Improving the efficacy of BCG immunotherapy by dose reduction: Cooperative Group CUETO Eur Urol 27 suppl 1 1995 13 18
31. M.D. Melekos I. Zarakovitis K. Dandinis BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: Results of a prospective randomized study using modified treatment schemes Int Urol Nephrol 28 1996 499 509
32. T. Okamura K. Tozawa Y. Yamada Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer J Urol 156 1996 967 971
33. F. Pagano A. Garbeglio C. Milani Prognosis of bladder cancer. I. Risk factors in superficial transitional cell carcinoma Eur Urol 13 1987 145 149
34. F. Pagano P. Bassi C. Milani A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective? J Urol 146 1991 32 35
35. F. Pagano P. Bassi N. Piazza Improving the efficacy of BCG immunotherapy by dose reduction Eur Urol 27 suppl 1 1995 19 22
36. F. Pages T.A. Flam A. Vieillefond p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors J Urol 159 1998 1079 1084
37. V. Pansadoro P. Emiliozzi L. Defidio Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: Long term results J Urol 154 1995 2054 2058
38. V.E. Reuter M.R. Melamed The lower urinary tract S. Sternberg Diagnostic Surgical Pathology 1994 Raven Press New York 1767 1805
39. E. Rintala K. Jauhiainen O. Alfthan Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer Eur Urol 20 1991 19 25
40. E. Rintala K. Jauhiainen P. Rajala Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder: The Finnbladder Group J Urol 154 1995 2050 2053
41. E. Rintala K. Jauhiainen E. Kaasinen Alternating mitomycin C and bacilluis Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer: Finnbladder Group J Urol 156 1996 56 59
42. M.S. Soloway Overview of treatment of superficial bladder cancer Urol 26 suppl 1985 18 27
43. M. Takashi K. Wakai Y. Ohno Evaluation of low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer Int Urol Nephrol 27 1995 723 733
44. R.J. Torrence L.R. Kavoussi W.J. Catalona Prognostic factors in patients treated with intravesical bacillus Calmette-Guerin for superficial bladder cancer J Urol 139 1988 941 944
45. P.D. Vegt J.A. Witjes W.P. Witjes A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder J Urol 153 1995 929 933
46. J.A. Witjes M.P. Fransen A.P. van der Meijden Use of maintenance intravesical bacillus Calmette-Guerin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer: Long term follow-up of a randomized phase 2 study Urol Int 51 1993 67 72
47. G.K. Zhang E.T. Uke W.C. Sharer Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder J Urol 155 1996 1907 1909